Clinical trials: Epidermolysis Bullosa Simplex
Epidermolysis Bullosa
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin
Dowling Meara type of epidermolysis bullosa simplex (EBS-DM) is a rare genodermatosis due to keratin 5 and 14 mutation, characterized by skin fragility and spontaneous or post traumatic blisters.
- Trial name
- NCT01340235
- Testing
- Oral erythromycin
- Where
- 4 sites in France
- Volunteers
- 8 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa
A Study to Evaluate ENERGI-F703EB Cream in Epidermolysis Bullosa
This is a phase II, intra-subject randomized, double-blind, vehicle-controlled, parallel, multicenter study to evaluate the safety and preliminary efficacy of ENERGI-F703EB Cream in subjects who are ≥ 18 years old with…
- Conditions
- Epidermolysis Bullosa (EB), Junctional Epidermolysis Bullosa, Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa
- Trial name
- NCT07858422
- Testing
- ENERGI-F703EB Cream, Matched vehicle cream
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Energenesis Biomedical Co., Ltd.
Epidermolysis Bullosa Simplex
Diacerin for the Treatment of Epidermolysis Bullosa Simplex
Epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) is one of the most severe subtypes of EBS. Blisters and erosions of the skin and mucous membranes upon minor trauma are the consequence of dominantly inherited mutations…
- Trial name
- NCT02470689
- Testing
- Diacerin cream
- Volunteers
- 50 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Epidermolysis Bullosa Simplex Dowling Meara
Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara
Introduction: Epidermolysis Bullosa Simplex-Dowling-Meara (DM-EBS) is a rare genodermatosis characterized by spontaneous or post traumatic large cutaneous blisters. No curative treatment is actually available.
- Trial name
- NCT01556308
- Testing
- Taking of liquid and top of blisters
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Epidermolysis Bullosa
Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa
The study aimed to assess the long-term safety of topical use of Zorblisa (SD-101-6.0) in participants with Epidermolysis Bullosa (EB).
- Trial name
- NCT02670330
- Testing
- SD-101-6.0 cream
- Where
- 30 sites in United States, Australia and 10 more
- Volunteers
- 152 people
- Sponsor
- Scioderm, Inc.
Epidermolysis Bullosa Simplex
A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex
This Phase II clinical study will assess the efficacy, safety and tolerability of topical TolaSure Gel in adults and pediatric patients (2 years of age and older) diagnosed with localized, intermediate, or severe epidermolysis…
- Trial name
- (TAMES) (NCT07027345)
- Testing
- 5% TolaSure Topical Gel
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- BioMendics, LLC
Epidermolysis Bullosa
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
The purpose of this study was to assess the continued safety of topical use of SD-101 cream (6%) in participants with Epidermolysis Bullosa (EB). Funding Source: FDA Office of Orphan Products Development
- Trial name
- NCT02090283
- Testing
- SD-101 dermal cream (6%)
- Where
- 7 sites in United States
- Volunteers
- 42 people
- Sponsor
- Scioderm, Inc.